Dr. Reddy’s Laboratories (RDY) Expected to Announce Quarterly Earnings on Wednesday

Dr. Reddy’s Laboratories (NYSE:RDY) is expected to be releasing its earnings data on Wednesday, January 29th. Analysts expect Dr. Reddy’s Laboratories to post earnings of $0.19 per share and revenue of $975,712.23 billion for the quarter. Persons that wish to register for the company’s earnings conference call can do so using this link.

Dr. Reddy’s Laboratories Stock Down 0.6 %

Shares of Dr. Reddy’s Laboratories stock opened at $14.81 on Wednesday. The business’s fifty day moving average price is $14.86 and its two-hundred day moving average price is $15.54. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.92 and a quick ratio of 1.36. The company has a market capitalization of $12.36 billion, a P/E ratio of 23.65 and a beta of 0.51. Dr. Reddy’s Laboratories has a 1-year low of $13.47 and a 1-year high of $16.89.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on RDY. Nomura cut Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research report on Thursday, December 19th. StockNews.com cut Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research report on Friday, December 6th. Finally, Barclays lowered their price target on Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 6th.

About Dr. Reddy’s Laboratories

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.